Glaukos Reports Record Net Sales in Third Quarter, Raises 2025 Full-Year Guidance
Published on October 30, 2025
ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, yesterday announced financial results for the third quarter ended September 30, 2025. The company reported record net sales of $133.5 million in Q3 2025, an increase of 38 percent year-over-year on a reported basis and 37 percent year-over-year on a constant currency basis, according to the announcement.